CYP1B1 genotype and risk of cardiovascular disease, pulmonary disease, and cancer in 50000 individuals

Pharmacogenetics and Genomics

Volumn 19, Issue 9, 2009, Pages 685-694

  Kaur Knudsen, Diljit ^a   Nordestgaard, Børge G ^a,c   Tybjaerg Hansen, Anne ^a,b,c   Bojesen, Stig E ^a,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

17b estradiol; Cancer; Cardiovascular disease; Chronic obstructive pulmonary disease; CYP1B1; Cytochrome P450 1B1; Ischemic cerebrovascular disease; Myocardial infarction; Polycyclic aromatic hydrocarbons; Single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450 1B1;

ADULT; AGED; ARTICLE; CANCER RISK; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LUNG CANCER; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; CROSS-SECTIONAL STUDIES; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENETICS, POPULATION; GENOTYPE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING;

NICOTIANA TABACUM;

EID: 70249124186     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833042cb     Document Type: Article

References (86)

1. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360:1155-1162.
2. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006; 6:947-960
3. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996; 56:2979-2984.
4. Nel AE, az-Sanchez D, Li N. The role of particulate pollutants in pulmonary inflammation and asthma: evidence for the involvement of organic chemicals and oxidative stress. Curr Opin Pulm Med 2001; 7:20-26.
5. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999; 20:1607-1613. (Pubitemid 29385452)
6. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. Functional analysis of six different polymorphic CYP1B1 enzyme variants found in an Ethiopian population. Mol Pharmacol 2002; 61:586-594.
7. Aklillu E, Ovrebo S, Botnen IV, Otter C, Ingelman-Sundberg M. Characterization of common CYP1B1 variants with different capacity for benzo[a]pyrene-7,8-dihydrodiol epoxide formation from benzo[a]pyrene. Cancer Res 2005; 65:5105-5111.
8. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000; 60:3440-3444.
9. Li D, Jiao L. Molecular epidemiology of pancreatic cancer. Int J Gastrointest Cancer 2003; 33:3-14.
10. Ramos KS, Moorthy B. Bioactivation of polycyclic aromatic hydrocarbon carcinogens within the vascular wall: implications for human atherogenesis. Drug Metab Rev 2005; 37:595-610.
11. Chen Z, Boreham J. Smoking and cardiovascular disease. Semin Vasc Med 2002; 2:243-252.
12. Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 2003; 46:91-111.
13. Burstyn I, Kromhout H, Partanen T, Svane O, Langard S, Ahrens W, et al. Polycyclic aromatic hydrocarbons and fatal ischemic heart disease. Epidemiology 2005; 16:744-750.
14. Curfs DM, Knaapen AM, Pachen DM, Gijbels MJ, Lutgens E, Smook ML, et al. Polycyclic aromatic hydrocarbons induce an inflammatory atherosclerotic plaque phenotype irrespective of their DNA binding properties. FASEB J 2005; 19:1290-1292.
15. Dubey RK, Jackson EK. Cardiovascular protective effects of 17beta-estradiol metabolites. J Appl Physiol 2001; 91:1868-1883.
16. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343:269-280.
17. Franklin W, Lowell FC, Michelson AL, Schiller IW. Chronic obstructive pulmonary emphysema; a disease of smokers. Ann Intern Med 1956; 45:268-274.
18. Burstyn I, Boffetta P, Heederik D, Partanen T, Kromhout H, Svane O, et al. Mortality from obstructive lung diseases and exposure to polycyclic aromatic hydrocarbons among asphalt workers. Am J Epidemiol 2003; 158:468-478.
19. Murray GI, Melvin WT, Greenlee WF, Burke MD. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 2001; 41:297-316.
20. Spivack SD, Hurteau GJ, Reilly AA, Aldous KM, Ding X, Kaminsky LS. CYP1B1 expression in human lung. Drug Metab Dispos 2001; 29:916-922.
21. Tang YM, Chen GF, Thompson PA, Lin DX, Lang NP, Kadlubar FF. Development of an antipeptide antibody that binds to the C-terminal region of human CYP1B1. Drug Metab Dispos 1999; 27:274-280.
22. Roos PH, Bolt HM. Cytochrome P450 interactions in human cancers: new aspects considering CYP1B1. Expert Opin Drug Metab Toxicol 2005; 1:187-202.
23. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999; 91:1194-1210.
24. Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006; 8:E101-E111.
25. Knaapen AM, Curfs DM, Pachen DM, Gottschalk RW, de Winther MP, Daemen MJ, et al. The environmental carcinogen benzo[a]pyrene induces expression of monocyte-chemoattractant protein-1 in vascular tissue: a possible role in atherogenesis. Mutat Res 2007; 621:31-41.
26. Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344:276-285.
27. Holt SK, Rossing MA, Malone KE, Schwartz SM, Weiss NS, Chen C. Ovarian cancer risk and polymorphisms involved in estrogen catabolism. Cancer Epidemiol Biomarkers Prev 2007; 16:481-489.
28. Rose PG. Endometrial carcinoma. N Engl J Med 1996; 335:640-649.
29. Subramanian A, Salhab M, Mokbel K. Oestrogen producing enzymes and mammary carcinogenesis: a review. Breast Cancer Res Treat 2007; 111:191-202.
30. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG. Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J 2002; 23:620-626.
31. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298:299-308.
32. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008; 299:2524-2532.
33. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 2008; 359:1897-1908.
34. Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. Integrin beta3 Leu33Pro homozygosity and risk of cancer. J Natl Cancer Inst 2003; 95:1150-1157
35. The Health Consequences of Smoking. A report of the Surgeon General. 2004. 2008.
36. Zhao W, Parrish AR, Ramos KS. Constitutive and inducible expression of cytochrome P450IA1 and P450IB1 in human vascular endothelial and smooth muscle cells4. In Vitro Cell Dev Biol Anim 1998; 34:671-673.
37. Benn M, Nordestgaard BG, Jensen JS, Tybjaerg-Hansen A. Polymorphisms in apolipoprotein B and risk of ischemic stroke. J Clin Endocrinol Metab 2007; 92:3611-3617. (Pubitemid 47435346)
38. Dahl M, Tybjaerg-Hansen A, Sillesen H, Jensen G, Steffensen R, Nordestgaard BG. Blood pressure, risk of ischemic cerebrovascular and ischemic heart disease, and longevity in alpha(1)-antitrypsin deficiency: the Copenhagen City Heart Study. Circulation 2003; 107:747-752. (Pubitemid 36222604)
39. Ellervik C, Tybjaerg-Hansen A, Appleyard M, Sillesen H, Boysen G, Nordestgaard BG. Hereditary hemochromatosis genotypes and risk of ischemic stroke. Neurology 2007; 68:1025-1031. (Pubitemid 46569137)
40. Freiberg JJ, Tybjaerg-Hansen A, Sillesen H, Jensen GB, Nordestgaard BG. Promotor polymorphisms in leukotriene C4 synthase and risk of ischemic cerebrovascular disease. Arterioscler Thromb Vasc Biol 2008; 28:990-996.
41. Frikke-Schmidt R, Nordestgaard BG, Schnohr P, Steffensen R, Tybjaerg-Hansen A. Mutation in ABCA1 predicted risk of ischemic heart disease in the Copenhagen City Heart Study Population. J Am Coll Cardiol 2005; 46:1516-1520. (Pubitemid 41446188)
42. Juul K, Tybjaerg-Hansen A, Marklund S, Heegaard NH, Steffensen R, Sillesen H, et al. Genetically reduced antioxidative protection and increased ischemic heart disease risk: the Copenhagen City Hheart Study. Circulation 2004; 109:59-65.
43. Stene MC, Frikke-Schmidt R, Nordestgaard BG, Grande P, Schnohr P, Tybjaerg-Hansen A. Functional promoter variant in zinc finger protein 202 predicts severe atherosclerosis and ischemic heart disease. J Am Coll Cardiol 2008; 52:369-377.
44. Tybjaerg-Hansen A, Jensen HK, Benn M, Steffensen R, Jensen G, Nordestgaard BG. Phenotype of heterozygotes for low-density lipoprotein receptor mutations identified in different background populations. Arterioscler Thromb Vasc Biol 2005; 25:211-215.
45. Wittrup HH, Andersen RV, Tybjaerg-Hansen A, Jensen GB, Nordestgaard BG. Combined analysis of six lipoprotein lipase genetic variants on triglycerides, high-density lipoprotein, and ischemic heart disease: cross-sectional, prospective, and case-control studies from the Copenhagen City Heart Study. J Clin Endocrinol Metab 2006; 91:1438-1445.
46. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301:2331-2339.
47. Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard BG. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann Intern Med 2002; 136:270-279.
48. Dahl M, Bowler RP, Juul K, Crapo JD, Levy S, Nordestgaard BG. Superoxide dismutase 3 polymorphism associated with reduced lung function in two large populations. Am J Respir Crit Care Med 2008; 178:906-912.
49. Juul K, Tybjaerg-Hansen A, Marklund S, Lange P, Nordestgaard BG. Genetically increased antioxidative protection and decreased chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173:858-864.
50. Anderson KE, Hammons GJ, Kadlubar FF, Potter JD, Kaderlik KR, Ilett KF, et al. Metabolic activation of aromatic amines by human pancreas. Carcinogenesis 1997; 18:1085-1092.
51. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371:1695-1709.
52. Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 2007; 17:731-742.
53. Cheung YL, Kerr AC, McFadyen MC, Melvin WT, Murray GI. Differential expression of CYP1A1, CYP1A2, CYP1B1 in human kidney tumours. Cancer Lett 1999; 139:199-205.
54. Cote ML, Wenzlaff AS, Bock CH, Land SJ, Santer SK, Schwartz DR, et al. Combinations of cytochrome P-450 genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study. Lung Cancer 2007; 55:255-262.
55. Franceschi S, Talamini R, Barra S, Baron AE, Negri E, Bidoli E, et al. Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx, and esophagus in northern Italy. Cancer Res 1990; 50:6502-6507. (Pubitemid 20348768)
56. Haverkos HW, Soon G, Steckley SL, Pickworth W. Cigarette smoking and cervical cancer: part I: a meta-analysis. Biomed Pharmacother 2003; 57:67-77.
57. Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, Donato F, et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer 2004; 110:598-604. (Pubitemid 38658026)
58. Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer 2005; 114:101-108.
59. Ko Y, Abel J, Harth V, Brode P, Antony C, Donat S, et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 2001; 61:4398-4404.
60. Liang G, Pu Y, Yin L. Rapid detection of single nucleotide polymorphisms related with lung cancer susceptibility of Chinese population. Cancer Lett 2005; 223:265-274
61. Muskhelishvili L, Thompson PA, Kusewitt DF, Wang C, Kadlubar FF. In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J Histochem Cytochem 2001; 49:229-236.
62. Nagai F, Hiyoshi Y, Sugimachi K, Tamura HO. Cytochrome P450 (CYP) expression in human myeloblastic and lymphoid cell lines. Biol Pharm Bull 2002; 25:383-385.
63. Pratt MM, Sirajuddin P, Poirier MC, Schiffman M, Glass AG, Scott DR, et al. Polycyclic aromatic hydrocarbon-DNA adducts in cervix of women infected with carcinogenic human papillomavirus types: an immunohistochemistry study. Mutat Res 2007; 624:114-123.
64. Sasaki M, Tanaka Y, Okino ST, Nomoto M, Yonezawa S, Nakagawa M, et al. Polymorphisms of the CYP1B1 gene as risk factors for human renal cell cancer. Clin Cancer Res 2004; 10:2015-2019.
65. Singh AP, Shah PP, Mathur N, Buters JT, Pant MC, Parmar D. Genetic polymorphisms in cytochrome P4501B1 and susceptibility to head and neck cancer. Mutat Res 2008; 639:11-19.
66. Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O. Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. Cancer Lett 2005; 221:185-190.
67. Uno S, Dragin N, Miller ML, Dalton TP, Gonzalez FJ, Nebert DW. Basal and inducible CYP1 mRNA quantitation and protein localization throughout the mouse gastrointestinal tract. Free Radic Biol Med 2008; 44:570-583.
68. Vineis P, Veglia F, Garte S, Malaveille C, Matullo G, Dunning A, et al. Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. Ann Oncol 2007; 18:1230-1242.
69. Watanabe J, Shimada T, Gillam EM, Ikuta T, Suemasu K, Higashi Y, et al. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 2000; 10:25-33.
70. Wenzlaff AS, Cote ML, Bock CH, Land SJ, Santer SK, Schwartz DR, et al. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 2005; 26:2207-2212.
71. Yoon KA, Kim JH, Gil HJ, Hwang H, Hwangbo B, Lee JS. CYP1B1, CYP1A1, MPO, and GSTP1 polymorphisms and lung cancer risk in never-smoking Korean women. Lung Cancer 2008; 60:40-46.
72. Doherty JA, Weiss NS, Freeman RJ, Dightman DA, Thornton PJ, Houck JR, et al. Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer1. Cancer Epidemiol Biomarkers Prev 2005; 14:357-366.
73. Gaudet MM, Chanock S, Lissowska J, Berndt SI, Yang XR, Peplonska B, et al. Genetic variation of Cytochrome P450 1B1 (CYP1B1) and risk of breast cancer among Polish women. Pharmacogenet Genomics 2006; 16:547-553.
74. Goodman MT, McDuffie K, Kolonel LN, Terada K, Donlon TA, Wilkens LR, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001; 10:209-216.
75. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. Production and actions of estrogens. N Engl J Med 2002; 346:340-352.
76. Hirata H, Hinoda Y, Okayama N, Suehiro Y, Kawamoto K, Kikuno N, et al. CYP1A1, SULT1A1, and SULT1E1 polymorphisms are risk factors for endometrial cancer susceptibility. Cancer 2008; 112:1964-1973.
77. Matyjasik J, Cybulski C, Masojc B, Jakubowska A, Serrano-Fernandez P, Gorski B, et al. CYP1B1 and predisposition to breast cancer in Poland. Breast Cancer Res Treat 2007; 106:383-388.
78. McGrath M, Hankinson SE, Arbeitman L, Colditz GA, Hunter DJ, De V. I. Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility. Carcinogenesis 2004; 25:559-565.
79. Paracchini V, Raimondi S, Gram IT, Kang D, Kocabas NA, Kristensen VN, et al. Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am J Epidemiol 2007; 165:115-125.
80. Rylander-Rudqvist T, Wedren S, Jonasdottir G, Ahlberg S, Weiderpass E, Persson I, et al. Cytochrome P450 1B1 gene polymorphisms and postmenopausal endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13:1515-1520.
81. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, Dahiya R. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Res 2003; 63:3913-3918.
82. Sasaki M, Kaneuchi M, Fujimoto S, Tanaka Y, Dahiya R. CYP1B1 gene in endometrial cancer. Mol Cell Endocrinol 2003; 202:171-176.
83. Sellers TA, Schildkraut JM, Pankratz VS, Vierkant RA, Fredericksen ZS, Olson JE, et al. Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:2536-2543.
84. Sillanpaa P, Heikinheimo L, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, et al. CYP1A1 and CYP1B1 genetic polymorphisms, smoking and breast cancer risk in a Finnish Caucasian population. Breast Cancer Res Treat 2007; 104:287-297.
85. Tao MH, Cai Q, Xu WH, Kataoka N, Wen W, Zheng W, et al. Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and endometrial cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 2006; 15:2570-2573.
86. Weischer M, Bojesen SE,Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol 2007; 25:57-63.